Related Experiment Video
Updated: Jun 10, 2025
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Trial watch: anticancer vaccination with dendritic cells
Francisca Borges1, Raquel S Laureano1, Isaure Vanmeerbeek1
1Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium.
Abstract:
Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), and utilizing maturation cocktails to ensure their effective activation. These matured DCs are then reinfused to elicit tumor-specific T-cell responses. While this approach has demonstrated the ability to generate potent immune responses, its clinical efficacy has been limited due to the immunosuppressive tumor microenvironment. Recent efforts have focused on enhancing the immunogenicity of DC-based vaccines, particularly through combination therapies with T cell-targeting immunotherapies. This Trial Watch summarizes recent advances in DC-based cancer treatments, including the development of new preclinical and clinical strategies, and discusses the future potential of DC-based vaccines in the evolving landscape of immuno-oncology.
Insights
Dendritic cell (DC) vaccines show promise for cancer treatment by stimulating immune responses. However, their effectiveness is limited by the tumor microenvironment, prompting research into combination therapies for enhanced anticancer immunity.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Dendritic cells (DCs) bridge innate and adaptive immunity, making them key targets for cancer vaccine development.
- Current DC-based immunotherapies involve ex vivo maturation and antigen pulsing of patient-derived DCs for T-cell activation.
- Clinical efficacy of DC vaccines is often hindered by the immunosuppressive tumor microenvironment.
Purpose of the Study:
- To review recent advancements in DC-based cancer treatments.
- To explore strategies for enhancing DC vaccine immunogenicity.
- To discuss the future role of DC vaccines in immuno-oncology.
Main Methods:
- Summary of preclinical and clinical strategies in DC-based cancer therapy.
- Analysis of combination therapies with T cell-targeting immunotherapies.
- Review of recent literature on DC vaccine development.
Main Results:
- DC-based vaccines can elicit potent tumor-specific immune responses.
- Combination therapies are being explored to overcome the immunosuppressive tumor microenvironment.
- New preclinical and clinical strategies are emerging to improve DC vaccine efficacy.
Conclusions:
- DC-based vaccines hold significant potential in cancer immunotherapy.
- Overcoming the immunosuppressive tumor microenvironment is crucial for clinical success.
- Future research focuses on optimizing DC vaccines and combining them with other immunotherapies for improved anticancer outcomes.
More Related Videos
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:51Vaccinations